Literature DB >> 10845410

Parenteral cephalosporin therapy in ambulatory care: advantages and disadvantages.

S Esposito1.   

Abstract

Outpatient parenteral antibiotic therapy (OPAT) programmes are effective, well tolerated and economically advantageous in carefully selected patient populations. Inclusion criteria for patient selection for OPAT include good clinical appearance and uncomplicated infection. By virtue of their favourable microbiological and pharmacological properties, cephalosporins in general, and ceftriaxone in particular, are the most widely prescribed antibiotics for OPAT worldwide. OPAT was largely created to prolong parenteral therapy following early discharge and has now been extended to community general practice. Indeed, more than 250000 treatments are performed in the US each year for a wide variety of serious infections, with an increase of 100% during the last 5 years. In 1994, an advisory committee was created in Canada to provide guidelines for home intravenous therapy. Of the 3 models that were defined (the visiting nurse model, the infusion centre model and the self-administration model), the OPAT self-administration model offers considerable cost savings and is probably largely utilised in a number of countries, such as Italy, where specific models have not been codified. Once the need for parenteral antibiotic therapy has been established, the choice of antibiotic is the second step in the decision-making process. Third generation cephalosporins are characterised by a number of important advantages in the OPAT setting, namely a favourable antibacterial spectrum, tolerability profile and patient compliance, as well as advantageous cost considerations. While the advantages of parenteral cephalosporin therapy in the ambulatory care setting outweigh the disadvantages in terms of cost effectiveness and rapid onset of action, adverse events such as pain at the injection site following intramuscular administration and phlebitis after intravenous infusion should be borne in mind.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10845410     DOI: 10.2165/00003495-200059003-00003

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  30 in total

1.  Home treatment of pulmonary infection in cystic fibrosis.

Authors:  J A Kuzemko
Journal:  Chest       Date:  1988-08       Impact factor: 9.410

2.  A program of outpatient parenteral antibiotic therapy for serious pediatric bacterial infections.

Authors:  R Dagan; M Einhorn
Journal:  Rev Infect Dis       Date:  1991 Jan-Feb

3.  Antibiotic management of outpatients with endocarditis due to penicillin-susceptible streptococci.

Authors:  D Stamboulian; P Bonvehi; C Arevalo; R Bologna; I Cassetti; V Scilingo; E Efron
Journal:  Rev Infect Dis       Date:  1991 Jan-Feb

4.  An analysis of decisions by European general practitioners to admit to hospital patients with lower respiratory tract infections. The European Study Group of Community Acquired Pneumonia (ESOCAP) of the European Respiratory Society.

Authors:  T Schaberg; G Gialdroni-Grassi; G Huchon; P Leophonte; F Manresa; M Woodhead
Journal:  Thorax       Date:  1996-10       Impact factor: 9.139

5.  Once-daily ceftriaxone in the outpatient treatment of paediatric infections.

Authors:  J S Bradley
Journal:  Chemotherapy       Date:  1991       Impact factor: 2.544

6.  Resistance to ceftriaxone and other beta-lactams in bacteria isolated in the community. The Vigil'Roc Study Group.

Authors:  F W Goldstein; Y Péan; J Gertner
Journal:  Antimicrob Agents Chemother       Date:  1995-11       Impact factor: 5.191

7.  Benefits of outpatient parenteral antibiotic therapy: to the individual, the institution, third-party payers and society.

Authors:  G Milkovich
Journal:  Int J Antimicrob Agents       Date:  1995-01       Impact factor: 5.283

8.  Home intravenous antibiotic therapy (HIVAT): indications, patients and antimicrobial agents.

Authors:  D N Williams
Journal:  Int J Antimicrob Agents       Date:  1995-01       Impact factor: 5.283

Review 9.  Experience with a physician-directed, clinic-based program for outpatient parenteral antibiotic therapy in the USA.

Authors:  A D Tice
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-07       Impact factor: 3.267

Review 10.  Outpatient parenteral antibiotic therapy. Management of serious infections. Part I: Medical, socioeconomic, and legal issues. The team concept.

Authors:  A D Tice
Journal:  Hosp Pract (Off Ed)       Date:  1993-06
View more
  2 in total

Review 1.  Piperacillin/tazobactam: a pharmacoeconomic review of its use in moderate to severe bacterial infections.

Authors:  M Young; G L Plosker
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

Review 2.  Outpatient parenteral antimicrobial therapy with ceftriaxone, a review.

Authors:  Christopher J A Duncan; David A Barr; R Andrew Seaton
Journal:  Int J Clin Pharm       Date:  2012-04-17
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.